TIMCC

Summary

TIMCC (TIM double twin CX3C motif chaperone, HGNC:25911) is a protein-coding gene on chromosome 2p13.3, encoding Protein FAM136A (Q96C01). It is a selective cancer dependency (DepMap: 63.7% of cell lines).

This gene encodes a mitochondrially localized protein that is highly conserved across species. The gene is expressed in a variety of tissues including human lymphoblast cells and rat neurosensorial epithelium of the cristaampullaris. A mutation in this gene has been associated with familial Meniere’s disease, a chronic disorder of the inner ear. Several pseudogenes of this gene are found on other chromosomes. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 84908 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Meniere disease (Limited, GenCC)
• GWAS associations: 6
• Clinical variants (ClinVar): 42 total — 1 pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 63.7% of screened cell lines
• MANE Select transcript: NM_001329752

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25911
Approved symbol	TIMCC
Name	TIM double twin CX3C motif chaperone
Location	2p13.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14668
Ensembl gene	ENSG00000035141
Ensembl biotype	protein_coding
OMIM	616275
Entrez	84908

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 4 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000037869, ENST00000430566, ENST00000438759, ENST00000450256, ENST00000460307, ENST00000498665, ENST00000711613, ENST00000910310

RefSeq mRNA: 6 — MANE Select: NM_001329752 NM_001329752, NM_001329753, NM_001329755, NM_001329757, NM_001329758, NM_032822

CCDS: CCDS1904, CCDS86849

Canonical transcript exons

ENST00000430566 — 3 exons

Exon	Start	End
ENSE00001639749	70301604	70302067
ENSE00001884677	70295976	70297477
ENSE00003609208	70300840	70300980

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 97.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 36.6521 / max 341.5905, expressed in 1824 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29027	19.9197	1807
29028	16.7325	1817

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parotid gland	UBERON:0001831	97.14	gold quality
body of pancreas	UBERON:0001150	95.18	gold quality
gingival epithelium	UBERON:0001949	93.49	gold quality
pancreas	UBERON:0001264	92.97	gold quality
rectum	UBERON:0001052	92.71	gold quality
mucosa of transverse colon	UBERON:0004991	92.33	gold quality
tongue squamous epithelium	UBERON:0006919	91.69	gold quality
gingiva	UBERON:0001828	91.62	gold quality
epithelium of nasopharynx	UBERON:0001951	91.52	gold quality
hair follicle	UBERON:0002073	91.51	gold quality
nasopharynx	UBERON:0001728	91.50	gold quality
duodenum	UBERON:0002114	91.29	gold quality
right lobe of liver	UBERON:0001114	90.97	gold quality
metanephros cortex	UBERON:0010533	90.76	gold quality
epithelial cell of pancreas	CL:0000083	90.65	gold quality
saliva-secreting gland	UBERON:0001044	90.64	gold quality
amniotic fluid	UBERON:0000173	90.39	gold quality
body of stomach	UBERON:0001161	90.26	gold quality
ganglionic eminence	UBERON:0004023	90.22	gold quality
islet of Langerhans	UBERON:0000006	90.12	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.05	gold quality
ventricular zone	UBERON:0003053	89.98	gold quality
squamous epithelium	UBERON:0006914	89.97	gold quality
choroid plexus epithelium	UBERON:0003911	89.95	gold quality
embryo	UBERON:0000922	89.81	gold quality
tonsil	UBERON:0002372	89.74	gold quality
germinal epithelium of ovary	UBERON:0001304	89.72	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.57	gold quality
caecum	UBERON:0001153	89.56	gold quality
pylorus	UBERON:0001166	89.52	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.65
E-CURD-112	yes	8.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

54 targeting TIMCC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-6715A-3P	99.83	68.05	1473
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-7161-5P	99.68	68.92	1592
HSA-MIR-548U	99.65	67.78	1463
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-3923	99.52	69.21	446
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-18A-5P	99.29	71.05	806

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 63.7% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• our findings suggest that novel mutations in FAM136A and DTNA genes are probably causal variants in FMD. (PMID:25305078)
• This study showed that FAM136A genes have been identified in familial Meniere’s disease. (PMID:27083884)
• FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series. (PMID:32098576)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	fam136a	ENSDARG00000098401
mus_musculus	Fam136a	ENSMUSG00000057497
rattus_norvegicus	Fam136a	ENSRNOG00000016273
drosophila_melanogaster	CG12661	FBGN0030071
drosophila_melanogaster	CG5323	FBGN0034362
drosophila_melanogaster	CG5327	FBGN0034363
caenorhabditis_elegans		WBGENE00014022

Protein

Protein identifiers

Protein FAM136A — Q96C01 (reviewed: Q96C01)

All UniProt accessions (5): A0AAA9YHH4, C9J2Y4, C9JF51, E7EQY1, Q96C01

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the FAM136 family.

RefSeq proteins (6): NP_001316681, NP_001316682, NP_001316684, NP_001316686, NP_001316687, NP_116211 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008560	DUF842_euk	Family

Pfam: PF05811

UniProt features (6 total): modified residue 3, initiator methionine 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96C01-F1	95.42	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 2, 124, 126

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 80 (showing top): GCACCTT_MIR18A_MIR18B, TGGTGCT_MIR29A_MIR29B_MIR29C, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, PATIL_LIVER_CANCER, MUELLER_PLURINET, YU_MYC_TARGETS_UP, GRYDER_PAX3FOXO1_ENHANCERS_IN_TADS, MARIADASON_RESPONSE_TO_BUTYRATE_SULINDAC_4, BERENJENO_TRANSFORMED_BY_RHOA_UP, CAIRO_LIVER_DEVELOPMENT_UP, GRYDER_PAX3FOXO1_TOP_ENHANCERS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_7, MANALO_HYPOXIA_DN, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

94 interactions, top by confidence:

A	B	Type	Score
FAM136A	RBFOX3	psi-mi:“MI:0914”(association)	0.640
SPMIP9	FAM136A	psi-mi:“MI:0915”(physical association)	0.620
NTAQ1	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
RUNX1T1	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
MAGEB4	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
FAM136A	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
MBD3	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
FAM136A	ANKRD11	psi-mi:“MI:0915”(physical association)	0.560
MEIS2	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
FAM136A	SMARCD1	psi-mi:“MI:0915”(physical association)	0.560
FAM136A	DPY30	psi-mi:“MI:0915”(physical association)	0.560
P4HA3	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
TTC19	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
PSMB1	FAM136A	psi-mi:“MI:0915”(physical association)	0.560
UPK3B	AP1G2	psi-mi:“MI:0914”(association)	0.560
STN1	SMCO3	psi-mi:“MI:0914”(association)	0.530
COLGALT2	COL1A1	psi-mi:“MI:0914”(association)	0.530
FAM136A	PIK3C2A	psi-mi:“MI:0914”(association)	0.530
AHNAK	FAM136A	psi-mi:“MI:0915”(physical association)	0.400
FAM136A	E7	psi-mi:“MI:0915”(physical association)	0.370
OTUB1		psi-mi:“MI:0914”(association)	0.350
OTUB1	EPM2A	psi-mi:“MI:0914”(association)	0.350

BioGRID (149): FAM136A (Affinity Capture-MS), FAM136A (Affinity Capture-MS), FAM136A (Affinity Capture-MS), FAM136A (Affinity Capture-MS), IDE (Affinity Capture-MS), CLPB (Affinity Capture-MS), CHCHD2 (Affinity Capture-MS), DHX30 (Affinity Capture-MS), HCCS (Affinity Capture-MS), ACSL5 (Affinity Capture-MS), CYB5R3 (Affinity Capture-MS), NDUFS6 (Affinity Capture-MS), ATP5H (Affinity Capture-MS), ECH1 (Affinity Capture-MS), BCKDHA (Affinity Capture-MS)

ESM2 similar proteins: A4QNC6, B0BN94, O74700, P0CR96, P0CR97, P0CS00, P0CS01, P30629, P62075, P62076, P62077, P62078, Q10481, Q2HJI3, Q2KIV2, Q3SZ93, Q4I6B0, Q4V7R1, Q59MI8, Q59R24, Q5ZIR8, Q616Q2, Q61TH2, Q63ZH8, Q66L32, Q6BN23, Q6BU42, Q6CM57, Q6DEM5, Q6DGJ3, Q6FK81, Q6GPY0, Q6PBU0, Q75DU7, Q7SBR3, Q8AVK1, Q90YI5, Q96C01, Q9CR98, Q9N408

Diamond homologs: A4QNC6, B0BN94, P30629, Q2HJI3, Q63ZH8, Q6PBU0, Q96C01, Q9CR98

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	21
Likely benign	6
Benign	8

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
140608	NM_001329752.2(FAM136A):c.547C>T (p.Gln183Ter)	Pathogenic

SpliceAI

401 predictions. Top by Δscore:

Variant	Effect	Δscore
2:70297473:CGGTC:C	acceptor_gain	1.0000
2:70297476:TC:T	acceptor_gain	1.0000
2:70297476:TCC:T	acceptor_loss	1.0000
2:70297477:CC:C	acceptor_gain	1.0000
2:70297477:CCTGT:C	acceptor_loss	1.0000
2:70297478:C:CC	acceptor_gain	1.0000
2:70297478:CTGTG:C	acceptor_loss	1.0000
2:70297479:T:G	acceptor_loss	1.0000
2:70297484:C:CT	acceptor_gain	1.0000
2:70297485:A:T	acceptor_gain	1.0000
2:70300836:TCA:T	donor_loss	1.0000
2:70300837:CA:C	donor_loss	1.0000
2:70300839:C:CG	donor_loss	1.0000
2:70300976:AGACC:A	acceptor_gain	1.0000
2:70300977:GACC:G	acceptor_gain	1.0000
2:70300978:ACC:A	acceptor_gain	1.0000
2:70300979:CC:C	acceptor_gain	1.0000
2:70300979:CCC:C	acceptor_gain	1.0000
2:70300980:CC:C	acceptor_gain	1.0000
2:70300981:C:CC	acceptor_gain	1.0000
2:70300981:C:T	acceptor_gain	1.0000
2:70300982:T:C	acceptor_loss	1.0000
2:70301920:GCTAC:G	donor_loss	1.0000
2:70301921:CTA:C	donor_loss	1.0000
2:70301923:A:C	donor_loss	1.0000
2:70301924:C:CA	donor_loss	1.0000
2:70301933:T:TA	donor_gain	1.0000
2:70297474:GGTC:G	acceptor_gain	0.9900
2:70297475:GTC:G	acceptor_gain	0.9900
2:70297480:G:C	acceptor_gain	0.9900

AlphaMissense

1605 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:70297449:C:T	C86Y	0.997
2:70300898:C:T	C57Y	0.997
2:70300960:G:C	S36R	0.997
2:70300960:G:T	S36R	0.997
2:70300962:T:G	S36R	0.997
2:70300969:G:C	F33L	0.997
2:70300969:G:T	F33L	0.997
2:70300970:A:G	F33S	0.997
2:70300971:A:G	F33L	0.997
2:70297448:G:C	C86W	0.996
2:70300865:A:T	V68D	0.996
2:70300897:G:C	C57W	0.996
2:70300899:A:G	C57R	0.996
2:70297449:C:A	C86F	0.995
2:70297449:C:G	C86S	0.995
2:70297450:A:G	C86R	0.995
2:70297450:A:T	C86S	0.995
2:70297460:G:C	C82W	0.995
2:70300853:A:G	L72P	0.995
2:70300878:C:G	A64P	0.995
2:70300898:C:A	C57F	0.995
2:70300951:A:C	C39W	0.995
2:70300952:C:T	C39Y	0.995
2:70297366:A:G	C114R	0.994
2:70297461:C:T	C82Y	0.994
2:70297462:A:G	C82R	0.994
2:70300898:C:G	C57S	0.994
2:70300899:A:T	C57S	0.994
2:70297464:C:G	R81P	0.993
2:70300844:A:G	F75S	0.993

dbSNP variants (sampled 300 via entrez): RS1000143235 (2:70298155 C>T), RS1000241990 (2:70297761 T>C), RS1001019439 (2:70303004 G>A), RS1002328801 (2:70302050 C>G,T), RS1002565479 (2:70300236 G>A,T), RS1002702859 (2:70300526 C>A), RS1002999971 (2:70299889 C>T), RS1004924044 (2:70295905 T>C), RS1004976540 (2:70296437 A>G), RS1005475785 (2:70301182 T>C), RS1005655834 (2:70303076 A>C), RS1005681536 (2:70301126 G>A), RS1005691512 (2:70298635 T>C), RS1005970199 (2:70299952 C>G,T), RS1006069414 (2:70299911 T>A)

Disease associations

OMIM: gene MIM:616275 | disease phenotypes: MIM:156000

GenCC curated gene-disease

Disease	Classification	Inheritance
Meniere disease	Limited	Unknown

Mondo (1): Meniere disease (MONDO:0007972)

Orphanet (1): NON RARE IN EUROPE: Menière disease (Orphanet:45360)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002481_1	Acne (severe)	5.000000e-06
GCST003802_4	Response to citalopram or escitalopram in depression	5.000000e-07
GCST006612_37	LDL cholesterol	2.000000e-08
GCST006614_47	Total cholesterol levels	2.000000e-11
GCST006661_199	Male-pattern baldness	3.000000e-08
GCST009391_905	Metabolite levels	7.000000e-07

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004574	total cholesterol measurement
EFO:0010442	triacylglycerol 58:8 measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008575	Meniere Disease	C09.218.568.217.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067302 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

4 potent at pChembl≥5 of 4 total, top 4 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.51	Kd	31.19	nM	CHEMBL3752910
7.37	ED50	42.95	nM	CHEMBL3752910
5.47	Kd	3364	nM	CHEMBL5653589
5.33	ED50	4631	nM	CHEMBL5653589

PubChem BioAssay actives

2 with measured affinity, of 4 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148361: Binding affinity to human FAM136A incubated for 45 mins by Kinobead based pull down assay	kd	0.0312	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148361: Binding affinity to human FAM136A incubated for 45 mins by Kinobead based pull down assay	kd	3.3637	uM

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, affects expression, affects cotreatment	3
aristolochic acid I	increases expression	1
FR900359	increases phosphorylation	1
tetrahydropalmatine	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
ochratoxin A	decreases expression	1
beta-methylcholine	affects expression	1
corosolic acid	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Dichlorodiphenyl Dichloroethylene	increases expression	1
Doxorubicin	decreases expression	1
Ivermectin	decreases expression	1
Smoke	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	increases methylation	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651403	Binding	Binding affinity to human FAM136A incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

5 cell lines: 2 transformed cell line, 2 cancer cell line, 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2WU	Abcam HEK293T FAM136A KO	Transformed cell line	Female
CVCL_B5H2	GENYOi007-A	Induced pluripotent stem cell	Female
CVCL_E7TW	FMD patient III.4 LCL	Transformed cell line	Female
CVCL_SM84	HAP1 FAM136A (-) 1	Cancer cell line	Male
CVCL_XN65	HAP1 FAM136A (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

31 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01574313	PHASE4	COMPLETED	Effect of Stellate Ganglion Block on Meniere’s Disease
NCT02529475	PHASE4	TERMINATED	Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)
NCT04815187	PHASE4	ACTIVE_NOT_RECRUITING	Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere’s Disease
NCT03664674	PHASE3	COMPLETED	Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere’s Disease
NCT04677972	PHASE3	COMPLETED	SPI-1005 for the Treatment of Meniere’s Disease
NCT05851508	PHASE3	RECRUITING	The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere’s Disease
NCT05420350	PHASE2	UNKNOWN	Lamotrigine and Bupropion for Meniere’s Disease
NCT06544434	PHASE2	RECRUITING	Laser Acupuncture for Meniere Disease
NCT04674735	PHASE1	WITHDRAWN	Safety of APSLXR in Patients Presenting Vertigo of Vestibular Origin or Meniere’s Disease
NCT04218123	PHASE2/PHASE3	COMPLETED	Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere’s Disease Outcomes
NCT04766853	PHASE1/PHASE2	COMPLETED	Verification of the Efficacy/safety of the Intratympanic Drug Delivery for Hearing Loss
NCT04794842	EARLY_PHASE1	UNKNOWN	Comparing Topical Tetracaine Drops to Topical Focal Phenol for Local Anesthesia During Intratympanic Steroid Injection
NCT00599560	Not specified	COMPLETED	Vasopressin and V2 Receptor in Meniere’s Disease
NCT02371798	Not specified	WITHDRAWN	Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?
NCT03520322	Not specified	TERMINATED	A Study of a Mastoid Device in Subjects With Ménière’s Disease
NCT03795675	Not specified	ACTIVE_NOT_RECRUITING	CI Following VS Removal or Labyrinthectomy
NCT04370366	Not specified	RECRUITING	Imaging of Endolymphatic Hydrops at 7T MRI
NCT04569175	Not specified	COMPLETED	Non Enhanced Labyrinth Imaging for the Detection of Endolymphatic Hydrops in Meniere’s Disease NELI Study
NCT04686695	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation Treatment on Meniere Disease
NCT04835688	Not specified	UNKNOWN	Ventilation Tube Insertion for Unilateral Menière’s Disease
NCT04902963	Not specified	COMPLETED	What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube?
NCT04935970	Not specified	UNKNOWN	Metabolic Disorders and Vertigo
NCT05322538	Not specified	NOT_YET_RECRUITING	Menier’s Disease - Bone Density Study
NCT05328895	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
NCT05424302	Not specified	RECRUITING	Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy
NCT05582148	Not specified	UNKNOWN	Meniere Disease and Hearing Aids
NCT05844657	Not specified	COMPLETED	Comprehensive Evaluation in Patients With Meniere’s Disease
NCT05960786	Not specified	COMPLETED	Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
NCT06278129	Not specified	UNKNOWN	Evaluation of the Diagnostic and Prognostic Efficacy of MRI in Acute Sensorineural Hearing Loss and Ménière’s Disease
NCT06544590	Not specified	COMPLETED	Transcutaneous Auricular Vagus Nerve Stimulation for Meniere Disease
NCT07272473	Not specified	RECRUITING	Effects of Cervical Mobilization on Dizziness, Balance, and Joint Position Sense in Patients With Meniere’s Disease